Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 70-74

  Robinson, William R ^a,b   Beyer, Julie ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Harrington Cancer Center   (United States)

Author keywords

Completion; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEMOGRAPHY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WITHHOLDING TREATMENT;

EID: 74249107606     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c7f670     Document Type: Article

References (13)

1. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwest Oncology Group, and the Eastern Cooperative Oncology Group.J Clin Oncol. 2001;19:1001-1007.
2. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin and intravenous cyclophosphamide for stage III ovarian cancer. N Eng J Med. 1996;335:1950-1955.
3. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase 3 trial of intravenous vs. intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:27-32.
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Eng J Med. 2006;354:34-43.
5. Ozols RF, Bundy BN, Greer BE, et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3183-3185.
6. Robinson WR, Coberly C, Beyer J, et al. Office-based intraperitoneal chemotherapy for ovarian cancer. J Oncol Pract. 2008;4:225-228.
7. Markman M, Smith HO, Moon J, et al. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxyrubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol. 2009;114:206-209.
8. Tiersten A, Liu PY, Smith H, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol. 2009;111:444-449.
9. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immun Invest. 2008;37: 215-225.
10. Markman M, Brady M, Hutson A, et al. Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Oncol. 2009;19:223-229.
11. Liakakos T, Thomakos N, Fine PM, et al. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg. 2001;18: 260-273.
12. Pryor HI II, O'Doherty E, Hart A, et al. Poly(glycerol sebacate) films prevent postoperative adhesions and allow laparoscopic placement. Surgery. 2009;146:490-497.
13. Zeng Q, Yu Z, You J, et al. Efficacy and safety of Seprafilm for preventing postoperative abdominal adhesion: systematic review and meta-analysis. World J Surg. 2007;31:2125-2131.